Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., MLC 5031, Cincinnati, OH, 45229, USA.
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Pediatr Radiol. 2021 Apr;51(4):640-648. doi: 10.1007/s00247-020-04881-0. Epub 2020 Nov 17.
Data suggest an increased risk of thyroid dysfunction following iodine-based contrast material (IBCM) in children.
To estimate the prevalence of thyroid stimulating hormone (TSH) abnormalities following exposure to a single dose of intravenous IBCM during computed tomography (CT) in young children.
Inpatients ≤24 months of age who underwent a single CT with intravenous IBCM (exposed cohort) or abdominal ultrasound (US) (unexposed cohort) examination and had a TSH value obtained within 90 days after imaging between January 2009 to November 2018 were identified. Propensity score matching with 20 variables was performed. Primary thyroid dysfunction was defined by abnormally high or low TSH value. Multivariable logistic regression identified risk factors, including intravenous IBCM, for thyroid dysfunction.
From the eligible 4,215 imaging examinations, 114 unique patients were included in the propensity matched population (n=57 per group). Thyroid dysfunction was identified in 14% (8/57) and 7% (4/57) of the IBCM-exposed and IBCM-unexposed cohorts, respectively. No patient in either cohort was started on thyroid hormone supplementation within the 3 months after imaging. Intravenous IBCM exposure was not a significant predictor of thyroid dysfunction on univariable (odds ratio [OR]=2.16, 95% confidence interval [CI]=0.61-7.64, P=0.23) or multivariable (OR=2.61, 95% CI=0.65-10.55, P=0.18) analyses. Significant independent predictors of post-imaging thyroid dysfunction included height (OR=1.25, P=0.0095) and trisomy 21 (OR=4.04, P=0.019).
Hospitalized children ≤24 months of age who received a single dose of intravenous IBCM for CT examination had a similar prevalence of TSH abnormalities compared to a propensity score matched group who underwent abdominal US. One dose of intravenous IBCM likely does not cause prolonged TSH abnormalities; however, larger studies are needed.
数据表明,儿童在使用碘基造影剂(IBCM)后甲状腺功能障碍的风险增加。
评估在小儿 CT 检查中单次静脉注射 IBCM 后促甲状腺激素(TSH)异常的发生率。
2009 年 1 月至 2018 年 11 月期间,纳入年龄≤24 个月且在单次 CT 检查中接受静脉 IBCM(暴露组)或腹部超声(US)检查(未暴露组),且在影像学检查后 90 天内获得 TSH 值的住院患儿。采用 20 个变量的倾向评分匹配。定义异常高或低 TSH 值为原发性甲状腺功能障碍。多变量逻辑回归确定甲状腺功能障碍的危险因素,包括静脉 IBCM。
在符合条件的 4215 次影像学检查中,114 名患儿在倾向评分匹配人群中(每组 57 例)。IBCM 暴露组和 IBCM 未暴露组分别有 14%(8/57)和 7%(4/57)的患儿出现甲状腺功能障碍。在影像学检查后 3 个月内,两组均无患儿开始服用甲状腺激素补充剂。单变量分析时,静脉 IBCM 暴露不是甲状腺功能障碍的显著预测因子(优势比[OR]=2.16,95%置信区间[CI]=0.61-7.64,P=0.23)或多变量分析时(OR=2.61,95% CI=0.65-10.55,P=0.18)。影像学后甲状腺功能障碍的显著独立预测因子包括身高(OR=1.25,P=0.0095)和 21 三体(OR=4.04,P=0.019)。
在接受单次 CT 检查中静脉注射 IBCM 的≤24 个月大的住院患儿中,促甲状腺激素异常的发生率与接受腹部 US 检查的匹配组相似。单次静脉注射 IBCM 可能不会引起 TSH 异常持续时间延长,但需要更大规模的研究。